title: Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients.
abstract: BACKGROUND
  Malabsorption due to exocrine pancreatic insufficiency is the main gastrointestinal problem in cystic fibrosis. Despite high doses of pancreatic enzyme supplements it is often not possible to normalize fat absorption. We compared a new high lipase pancreatic enzyme preparation (Pancrease-HL; Cilag, Brussels, Belgium), containing enteric coated microspheres with 25,000 U of lipase, 22,500 U of amylase and 1250 U of protease per capsule, with regular Pancrease capsules, containing 5000 U of lipase, 2900 U of amylase and 330 U of protease per capsule.
  
  
  METHODS
  In a randomized double-blind crossover study, 13 cystic-fibrosis patients (6 male, 7 female, mean age 27.7 years) received either four capsules of Pancrease t.d.s. or one capsule of Pancrease-HL t.d.s. Patients took 20 mg omeprazole daily to raise intra-duodenal pH and thus optimize release of enzymes from the enteric coated microspheres.
  
  
  RESULTS
  With four capsules of Pancrease t.d.s., mean fat excretion was 15.4% and mean nitrogen excretion was 19.9% vs. 15.5% fat and 19.9% nitrogen excretion with one capsule Pancrease-HL t.d.s. Fat and protein energy loss (as a percentage of total daily intake) was 18.3% with Pancrease and 18.2% with Pancrease-HL. The differences were not statistically significant. Pancrease-HL was well tolerated, with no difference in abdominal pain or general well-being scores. The number and average weight of stools passed remained the same.
  
  
  CONCLUSIONS
  One capsule of Pancrease-HL appears to be equivalent to four capsules of regular Pancrease. Treatment with less capsules per day with the same efficacy may facilitate patient compliance.
authors.affiliation: Department of Pulmonology, Leyenburg Hospital, The Hague, The Netherlands.
authors.forename: K H
authors.initials: KH
authors.lastname: Gan
authors.forename: H G
authors.initials: HG
authors.lastname: Heijerman
authors.forename: W P
authors.initials: WP
authors.lastname: Geus
authors.forename: W
authors.initials: W
authors.lastname: Bakker
authors.forename: C B
authors.initials: CB
authors.lastname: Lamers
mesh_terms: D000328:Adult; D003550:Cystic Fibrosis / Q000188:drug therapy*; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D008049:Lipase / Q000627:therapeutic use*; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D009584:Nitrogen / Q000652:urine; D009853:Omeprazole / Q000627:therapeutic use; D010194:Pancreatin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D010194:Pancreatin; D008049:Lipase; D009853:Omeprazole; D009584:Nitrogen